Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States

American Journal of Gastroenterology

Volumn 93, Issue 9, 1998, Pages 1432-1435

  Vakil, Nimish ^a   Hahn, Beth ^b   McSorley, D ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATION; CONTROLLED STUDY; DUODENUM ULCER; FEMALE; GEOGRAPHIC DISTRIBUTION; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; UNITED STATES;

ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DRUG RESISTANCE, MICROBIAL; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED;

EID: 0032173042     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.1998.455_t.x     Document Type: Article

References (28)

1. 1. Marshall BJ, Goodwin CS, Warren JR, et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988;2:1437-42.
2. 2. Peterson WL, Cicola AA, Sykes DL. Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H pylori and reducing ulcer recurrence. Aliment Pharmacol Ther 1996; 10:25-61.
3. 3. Logan R, Bardhan K, Celestin L. Eradication of H pylori and prevention of recurrence of duodenal ulcer: A randomized, double blind multicentre trial of omeprazole with and without clarithromycin. Aliment Pharmacol Ther 1995;9:417-23.
4. 4. Megraud F, Lehn N, Lin T, et al. The MACH-2 study. Helicobacter pylori resistance to antimicrobial agents and its influence on clinical outcome. Gastroenterology 1997;112:A218.
5. 5. Craft JC, Olson C, Siepman N, Edmonds A. Clarithromycin resistance in US and European patients treated with clarithromycin and omeprazole for duodenal ulcer disease associated with H. pylori infection. Am J Gastroenterol 1995;90:1579 (abstract).
6. 6. Weissfeld A, Simmons D, Rose P, et al. Susceptibility of Helicobacter pylori to clarithromycin and amoxicillin in the US. Gastroenterology 1997;112:A329 (abstract).
7. 7. NIH Consensus Development Panel on Helicobacter pylori in peptic ulcer disease. Helicobacter pylori in peptic ulcer disease. JAMA 1994; 272:65-9.
8. 8. Hachem C, Clarridge J, Reddy R, et al. Antimicrobial susceptibility testing of Helicobacter pylori. Diagn Microbiol Infect Dis 1996;24: 37-41.
9. 9. Utrup LJ, Tanaka SK, Olson CA, Graham DY. Clarithromycin susceptibility testing breakpoints for Helicobacter pylori. Gut 1996;39: A11.
10. 10. Mann H, Osato M, Graham D, Webb D. A comparison of E-test to agar dilution in detecting intermediate and borderline resistant susceptibilities to clarithromycin in vitro. Gastroenterology 1997;112:A209.
11. 11. Megraud F. H pylori resistance to antibiotics. In: Hunt RH, Tytgat GNJ, eds. Helicobacter pylori, basic mechanisms to clinical cure. Dodrecht, Netherlands: Kluwer Academic Publications, 1994:570-83.
12. 12. Versalovic J, Shortridge D, Kibler K, et al. Mutations in 23S rRNA are associated with Clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother 1996;40:477-80.
13. 13. DeKoster E, Cozzoli A, Jonas C, et al. Six years resistance of Helicobacter pylori to macrolides and imidazoles. Gut 1996;39 (supplement 2):A5.
14. 14. Cayla R, Lamouiliatte H, Megraud F, Quinton A. Primary resistance of Helicobacter pylori strains to metronidazole and clarithromycin in France in 1993. Gastroenterology 1994;106:A61 (abstract).
15. 15. Conroy MC, deKorwin J, Lozniewski A, Weber M. Resistance of Helicobacter pylori to clarithromycin and metronidazole in Eastern France. Gut 1996;39 (supplement 2):A6 (abstract).
16. 16. Xia HX, Keane CT, O'Morain CA. A 5 yr survey of metronidazole and clarithromycin resistance in clinical isolates of Helicobacter pylori. Gut 1996;39 (supplement 2):A6 (abstract).
17. 17. Van Zwet AA, deBoer W, Schneeberger P, et al. Prevalence of primary Helicobacter pylori resistance to Metronidazole and clarithromycin in the Netherlands. Eur J Clin Microbiol Infect Dis 861-4.
18. 18. Glupczynski Y, Goutier S, Van den Borre C, et al. Comparative in vitro activity of faropenem and of ketolides against recent Belgian clinical isolates of Helicobacter pylori. Gut 1996;39 (supplement 2):A7.
19. 19. Best LM, Haldane HJM, Veldhuyzen van Zanten SJG. Susceptibility of H. pylori in Canada to Clarithromycin and metronidazole. Gut 1996;39 (supplement 2):A13.
20. 20. Bell GD, Powell K, Burridge S, et al. Experience with triple anti-Helicobacter pylori eradication therapy: Side-effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resistance. Aliment Pharmacol Ther 1992;6:427-35.
21. 21. Penston JG, Mistry KR. Eradication of Helicobacter pylori in general practice. Aliment Pharmacol Ther 1996;10:139-45.
22. 22. Ebell MH, Warbasse L, Brenner C. Evaluation of the dyspeptic patient: A cost-utility study. J Fam Pract 1987;44:545-55.
23. 23. Roll J, Weng A, Newman J. Diagnosis and treatment of Helicobacter pylori infection among California Medicare patients. Arch Intern Med 1997;17:994-8.
24. 24. Forman D, Newell DG, Fullerton F, et al. Association between infection with Helicobacter pylori and risk of gastric cancer: Evidence from a prospective investigation. Br Med J 1991;302:1302-5.
25. 25. Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk for gastric carcinoma. N Engl J Med 1991;325: 1127-31.
26. 26. Parsonnet J, Harris RA, Hack HM, Owens DK. Modeling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: A mandate for clinical trials. Lancet 1996;348:150-4.
27. 27. Fennerty MB, Lieberman DL, Magaret N. Effectiveness of H pylori treatment regimens in clinical practice: A community based outcomes study. Gastroenterology 1997;112:A14(abstract).
28. 28. Osato M, Graham DY, Vakil N, et al. Development of Clarithromycin resistance is 2.7 times less likely with ranitidine bismuth citrate than with omeprazole. Gastroenterology 1998;114:A249 (abstract).